Colorectal cancer (CRC), a leading cause of cancer-related death worldwide, evolves as a
result of the stepwise accumulation of a series of genetic and epigenetic alterations in the …

Epigenetic drug discovery field has evidenced significant advancement in the recent times.
A plethora of small molecule inhibitors have progressed to clinical stage investigations and …

Abstract Anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)
antibodies are currently used in the clinic to interupt the PD-1/PD-L1 immune checkpoint …

Post-translational modifications of histones by protein methyltransferases (PMTs) and
histone demethylases (KDMs) play an important role in the regulation of gene expression …

Introduction: The hybridization of biologically active molecules is a powerful tool for drug
discovery used to target a variety of diseases. It offers the prospect of better drugs for the …

Hydroxyquinolines are heterocyclic compounds characterized by a moderate metal-binding
affinity. The interest in 8-hydroxyquinolines has grown exponentially in the last two decades …

Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an
epigenetic enzyme able to demethylate specific lysine residues of histone H3, namely …

Privileged structures can bind to a diverse range of targets with high affinities, thus
benefiting the discovery of novel bioactive agents. 8-Hydroxyquinoline derivatives represent …

Histone lysine‐specific demethylase 1 (LSD1) is the first discovered and reported histone
demethylase by Dr. Shi Yang's group in 2004. It is classified as a member of amine oxidase …

There is increasing interest in targeting histone N-methyl-lysine demethylases (KDMs) with
small molecules both for the generation of probes for target exploration and for therapeutic …